The 5-HT2A partial agonist R-MDMA reduces psychosis-like behaviour in the MPTP-lesioned non-human primate model of Parkinson's disease

被引：0
|
作者：
Huot, P.
Johnston, T. H.
Lewis, K. D.
Reyes, G.
Fox, S. H.
Piggott, M. J.
Brotchie, J. M.
机构：
来源：
MOVEMENT DISORDERS | 2011年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
837
引用
收藏
页码：S281 / S281
页数：1
相关论文
共 18 条
  • [1] Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease
    Visanji, Naomi P.
    Gomez-Ramirez, Jordi
    Johnston, Tom H.
    Pires, Donna
    Voon, Valerie
    Brotchie, Jonathan M.
    Fox, Susan H.
    MOVEMENT DISORDERS, 2006, 21 (11) : 1879 - 1891
  • [2] Dopamine receptor agonists and levodopa have similar propensity to induce psychosis-like behaviour in the MPTP-lesioned primate model of Parkinson's disease
    Fox, Susan H.
    Visanji, Naomi P.
    Johnston, Tom H.
    Voon, Valerie
    Brotchie, Jonathan M.
    ANNALS OF NEUROLOGY, 2006, 60 : S75 - S75
  • [3] The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future
    Bjorklund, Anders
    Cenci, M. Angela
    RECENT ADVANCES IN PARKINSONS DISEASE: TRANSLATIONAL AND CLINICAL RESEARCH, 2010, 184 : 133 - 157
  • [4] Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease
    McFarland, Krista
    Price, Diana L.
    Bonhaus, Douglas W.
    BEHAVIOURAL PHARMACOLOGY, 2011, 22 (07): : 681 - 692
  • [5] Synergistic anti-dyskinetic effect of topiramate and amantadine in the MPTP-lesioned non-human primate model of Parkinson's disease
    Kobylecki, C.
    Crossman, A. R.
    Paula, R.
    MOVEMENT DISORDERS, 2010, 25 (07) : S402 - S402
  • [6] Evolution of the "short duration" response to L-DOPA in the MPTP-lesioned non-human primate model of Parkinson's disease
    Mestre, T. A.
    Johnston, T. H.
    Brotchie, J. M.
    Fox, S. H.
    MOVEMENT DISORDERS, 2010, 25 (07) : S417 - S417
  • [7] 5-HT2A blockade for dyskinesia and psychosis in Parkinson’s disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review
    Cynthia Kwan
    Imane Frouni
    Dominique Bédard
    Stephen G. Nuara
    Jim C. Gourdon
    Adjia Hamadjida
    Philippe Huot
    Experimental Brain Research, 2019, 237 : 435 - 442
  • [8] 5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review
    Kwan, Cynthia
    Frouni, Imane
    Bedard, Dominique
    Nuara, Stephen G.
    Gourdon, Jim C.
    Hamadjida, Adjia
    Huot, Philippe
    EXPERIMENTAL BRAIN RESEARCH, 2019, 237 (02) : 435 - 442
  • [9] Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease
    Price, Diana L.
    Bonhaus, Douglas W.
    McFarland, Krista
    BEHAVIOURAL PHARMACOLOGY, 2012, 23 (04): : 426 - 433
  • [10] Evaluation of the effect of adding a mGlu2/3 orthosteric antagonist to a highly selective 5-HT2A antagonist on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
    Nuara, S.
    Gourdon, J.
    Huot, P.
    MOVEMENT DISORDERS, 2022, 37 : S314 - S314
12